Avalo Therapeutics (US:AVTX) — Company Overview, News & Financial Data
Avalo Therapeutics develops innovative treatments for autoimmune and rare diseases through rigorous clinical trials.
Avalo Therapeutics
Avalo Therapeutics (NASDAQ:AVTX) focuses on discovering and developing innovative treatments for patients suffering from complex autoimmune and rare diseases. The company’s operations are mainly concentrated on advancing its pipeline of unique drug candidates through various stages of clinical trials, with the aim to provide new, effective options for conditions with high unmet medical needs. Avalo's projects span a wide range of disorders, including but not limited to, immunology and rare diseases, where the goal is to significantly improve patients' quality of life. Avalo is dedicated to achieving breakthroughs in treatment through rigorous research, clinical development, and strategic collaborations.
Snapshot
Operations
Products and/or services of Avalo Therapeutics
- AVTX-002, an investigational therapy for Crohn’s disease and Ulcerative Colitis.
- AVTX-007, a potential treatment for asthma and allergic diseases by addressing imbalances in the immune system.
- AVTX-006, exploring novel approaches for rare diseases with a focus on genetic disorders.
- Research partnership projects with leading pharmaceutical companies to develop next-generation biologics.
Avalo Therapeutics executive team
- Dr. Garry A. Neil M.D.President, CEO & Director
- Mr. Christopher Ryan Sullivan CPACFO & Head of Investor relations
- Dr. Mittie Doyle FACR, M.D.Chief Medical Officer
- Dr. Solomon H. Snyder M.D.Founder and Chairman of Scientific Advisory Board
- Dr. Barbara S. Slusher Ph.D.Founder and Member of Scientific Advisory Board
- Mr. Paul C. Varki J.D., M.P.HChief Legal Officer
- Ms. Ashley IvanowiczSenior Vice President of Human Resources
- Ms. Colleen MatkowskiSenior Vice President of Global Regulatory Affairs & Quality Assurance
- Dr. Dino C. Miano Ph.D.Senior Vice President of CMC & Technical Operations
- Ms. Jennifer RileyChief Strategy Officer